Ground-State Descriptors Predict ROS Generation Efficiency and Enable Rational Design of Sonosensitizers for PROTAC-Enhanced Sono-Immunotherapy
Journal of the American Chemical Society · 2026
DOI: 10.1021/jacs.6c09901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Xiaoyu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, Ministry of Education Key Laboratory for the Synthesis and Applicatio…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Immunotherapy, Drug Design, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), Hainan Provincial Natural Science Foundation of China, Program for Excellent Young and Middle-Aged Sci-Tech Innovation Teams of Hubei Universities.
Abstract (Originalsprache)
Sonodynamic therapy (SDT) offers deep-tissue penetration but is limited by the lack of reliable strategies to predict intersystem crossing efficiency in sonosensitizers. Here, we identify two ground-state electronic descriptors, namely, the orbital center-of-mass distance (DH–L) and the orbital overlap integral (VH–L), that quantitatively correlate with intersystem crossing rates governed by orbital transition characteristics. These descriptors avoid computationally intensive excited-state calculations while maintaining strong predictive power. Guided by this strategy, we developed a series of donor–acceptor sonosensitizers with enhanced reactive oxygen species (ROS) generation under ultrasound (US) irradiation, as validated by both theoretical analysis and experimental measurements. The optimized sonosensitizer was further formulated into DPBRMN NPs that incorporate a hypoxia-responsive, BRD4-targeted PROTAC prodrug. This integrated platform enables tumor-selective ROS production together with in situ protein degradation-mediated immune activation, leading to effective suppression of primary tumors and distant metastases. This work establishes a descriptor-guided framework for sonosensitizer design and provides a molecular strategy for integrating sonodynamic therapy with targeted protein degradation to enhance cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Health Science and Engin…
- College of Materials Science and Engineering, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen518060, China.
- School of Chemistry and Chemical Engineering, Hainan University, Haikou570228, China.
ORCID-Profile: Mingle Li, Weijie Chi, Zhiqiang Mao, Zhihong Liu
Förderung
- National Natural Science Foundation of China (NSFC)
- Hainan Provincial Natural Science Foundation of China
- Program for Excellent Young and Middle-Aged Sci-Tech Innovation Teams of Hubei Universities
Zitieren
APA
Wang, X., Bian, C., Zhao, J., Jiang, X., Li, M., Chi, W., Mao, Z., & Liu, Z. (2026). Ground-State Descriptors Predict ROS Generation Efficiency and Enable Rational Design of Sonosensitizers for PROTAC-Enhanced Sono-Immunotherapy. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c09901
Vancouver
Wang X, Bian C, Zhao J, Jiang X, Li M, Chi W, et al. Ground-State Descriptors Predict ROS Generation Efficiency and Enable Rational Design of Sonosensitizers for PROTAC-Enhanced Sono-Immunotherapy. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c09901
BibTeX
@article{Wang2026,
author = {Wang, Xiaoyu and Bian, Changyu and Zhao, Jiang and Jiang, Xuyuan and Li, Mingle and Chi, Weijie and Mao, Zhiqiang and Liu, Zhihong},
title = {Ground-State Descriptors Predict ROS Generation Efficiency and Enable Rational Design of Sonosensitizers for PROTAC-Enhanced Sono-Immunotherapy},
journal = {Journal of the American Chemical Society},
year = {2026},
doi = {10.1021/jacs.6c09901}
}
EUVIMED